Aurinia Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 20, 2026, reports a comprehensive management transition at Aurinia Pharmaceuticals Inc. The filing details the departure of the entire existing executive team and the Board Chair, alongside the appointment of new leadership effective March 23, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
Departure of Officers and Directors: Effective March 20, 2026, the following officers ceased to serve: Peter Greenleaf (President, CEO, and Director), Matthew Donley (COO), Gregory Keenan, M.D. (CMO), and Joseph Miller (CFO). Mr. Greenleaf resigned from the Board effective March 21, 2026. He will serve as a consultant for three months at an hourly rate of $600 to facilitate the transition.
Appointment of New Officers: Effective March 23, 2026, the Board appointed:
- Kevin Tang: Chief Executive Officer and Principal Executive Officer. Mr. Tang, previously the Board Chair since 2024, will receive no salary, bonuses, or equity awards.
- Ryan Cole: Chief Operating Officer. Annual base salary of $300,000, target bonus of 50% of base, and 150,000 new hire stock options.
- Michael Hearne: Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer. Annual base salary of $300,000, target bonus of 50% of base, and 150,000 new hire stock options.
Board Governance: The Board created the position of Lead Independent Director and elected Craig Johnson to the role effective March 21, 2026.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. The primary contingency noted is the management transition, which includes a three-month consulting period for the outgoing CEO to ensure operational continuity.
Investor Verification Checklist
- Verify the effective dates of the new executive appointments (March 23, 2026) versus the departure of the prior team (March 20-21, 2026).
- Confirm the compensation structure for the new COO and CFO, specifically the 150,000 share option grants and 50% target bonuses.
- Review the attached press release (Exhibit 99.1) for strategic rationale behind the leadership change.
- Monitor upcoming filings for the first financial report under the new CFO, Michael Hearne.